BPMC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BPMC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-14), Blueprint Medicines's share price is $93.19. Blueprint Medicines's Book Value per Share for the quarter that ended in Sep. 2024 was $4.94. Hence, Blueprint Medicines's PB Ratio of today is 18.88.
The historical rank and industry rank for Blueprint Medicines's PB Ratio or its related term are showing as below:
During the past 11 years, Blueprint Medicines's highest PB Ratio was 44.53. The lowest was 2.80. And the median was 5.81.
During the past 12 months, Blueprint Medicines's average Book Value Per Share Growth Rate was 47.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -56.20% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -20.90% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Blueprint Medicines was 21.40% per year. The lowest was -56.20% per year. And the median was 16.75% per year.
The historical data trend for Blueprint Medicines's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Blueprint Medicines Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
PB Ratio | Get a 7-Day Free Trial | 8.50 | 4.41 | 6.53 | 5.10 | 43.18 |
Blueprint Medicines Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
PB Ratio | Get a 7-Day Free Trial | 15.05 | 43.18 | 19.11 | 21.26 | 18.74 |
For the Biotechnology subindustry, Blueprint Medicines's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Blueprint Medicines's PB Ratio distribution charts can be found below:
* The bar in red indicates where Blueprint Medicines's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Blueprint Medicines's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Sep. 2024) |
= | 93.19 | / | 4.935 | |
= | 18.88 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Blueprint Medicines (NAS:BPMC) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Blueprint Medicines's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Kate Haviland | officer: Chief Business Officer | BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139 |
Christina Rossi | officer: Chief Commercial Officer | 45 SIDNEY STREET, BLUEPRINT MEDICINES CORPORATION, CAMBRIDGE MA 02139 |
Lonnel Coats | director | 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381 |
Jeffrey W. Albers | director, officer: CEO & President | BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142 |
Fouad Namouni | officer: President, R and D | 535 BOYLSTON ST., 2ND FLOOR, BOSTON MA 02116 |
Michael Landsittel | officer: Principal FAO | BLUEPRINT MEDICINES CORP., 214 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142 |
Philina Lee | officer: Chief Commercial Officer | C/O FUSION PHARMACEUTICALS, INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P OA6 |
Debra Durso-bumpus | officer: Chief People Officer | C/O BLUEPRINT MEDICINES CORORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139 |
Percy H. Carter | officer: Chief Scientific Officer | C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139 |
L. Becker Hewes | officer: Chief Medical Officer | C/O BLUEPRINT MEDICINES, CORPORATION, CAMBRIDGE MA 02139 |
Ariel Hurley | officer: Principal Accounting Officer | C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139 |
Christopher K. Murray | officer: SVP, Technical Operations | C/O BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139 |
Tracey L Mccain | officer: EVP and Chief Legal Officer | C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139 |
John Tsai | director | BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139 |
Habib J Dable | director | C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139 |
From GuruFocus
By PRNewswire • 04-04-2024
By Marketwired • 05-20-2024
By GuruFocus Research • 03-23-2024
By PRNewswire • 06-13-2024
By GuruFocus Research • 06-06-2024
By GuruFocus Research • 05-03-2024
By GuruFocus Research • 05-03-2024
By PRNewswire • 04-11-2024
By GuruFocus Research • 08-02-2024
By GuruFocus News • 10-31-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.